|
|
|
|
pmid:
|
Breuer O |
Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma. |
1995 |
J. Lipid Res. |
pmid:8656065
|
Breuer O et al. |
The oxysterols cholest-5-ene-3 beta,4 alpha-diol, cholest-5-ene-3 beta,4 beta-diol and cholestane-3 beta,5 alpha,6 alpha-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques. |
1996 |
Biochim. Biophys. Acta |
pmid:8695664
|
Bodin K et al. |
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. |
2001 |
J. Biol. Chem. |
pmid:11514559
|
Bodin K et al. |
Metabolism of 4 beta -hydroxycholesterol in humans. |
2002 |
J. Biol. Chem. |
pmid:12077124
|
Rontani JF and Aubert C |
Electron ionization mass spectral fragmentation of cholestane-3beta,4alpha,5alpha-triol and cholestane-3beta,5alpha,6alpha/beta-triol bis- and tris-trimethylsilyl derivatives. |
2005 |
Rapid Commun. Mass Spectrom. |
pmid:15954177
|
Niemi M et al. |
Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. |
2006 |
Pharmacogenet. Genomics |
pmid:16847425
|
Diczfalusy U et al. |
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. |
2008 |
Pharmacogenet. Genomics |
pmid:18300941
|
Wide K et al. |
Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. |
2008 |
Br J Clin Pharmacol |
pmid:18279471
|
Josephson F et al. |
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. |
2008 |
Eur. J. Clin. Pharmacol. |
pmid:18458892
|
Kanebratt KP et al. |
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. |
2008 |
Clin. Pharmacol. Ther. |
pmid:18650803
|
Lütjohann D et al. |
4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. |
2009 |
Int J Clin Pharmacol Ther |
pmid:19954708
|
Tomalik-Scharte D et al. |
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? |
2009 |
Clin. Pharmacol. Ther. |
pmid:19458613
|
Honda A et al. |
Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. |
2009 |
J. Lipid Res. |
pmid:18815436
|
Allmyr M et al. |
Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones. |
2009 |
Basic Clin. Pharmacol. Toxicol. |
pmid:19686543
|
Diczfalusy U et al. |
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. |
2009 |
Br J Clin Pharmacol |
pmid:19006545
|
Yang Z and Rodrigues AD |
Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? |
2010 |
J Clin Pharmacol |
pmid:20197489
|
Goodenough AK et al. |
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. |
2011 |
Chem. Res. Toxicol. |
pmid:21728364
|
Peters J et al. |
Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. |
2011 |
Drug Metab. Dispos. |
pmid:21690264
|
Diczfalusy U et al. |
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. |
2011 |
Br J Clin Pharmacol |
pmid:21219398
|